I. Overview of DMF
Definition: A DMF is a submission to the FDA containing confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storage of drugs. It may also include other types of information such as toxicological data and shared system Risk Evaluation and Mitigation Strategies (REMS).
Features: DMF holders can authorize one or more applicants or manufacturers to reference information in the DMF without disclosing that information to them.
II. Types of DMF
Type II: Drug substances, drug substance intermediates, materials used in their production, or drug products.
Type III: Relates to packaging materials, which should be identified by type (e.g., bottles) and material of construction (e.g., high-density polyethylene). They can be combined to form container-closure systems (e.g., syringe barrel and plunger).
Type IV: Includes excipients, colorants, flavors, essences, or materials used in their preparation.
Type V: FDA-acceptable reference information, such as shared system REMS, sterile processing facilities, and toxicological studies.
III. DMF Filing Process
DMF Number Application: Apply for a secure email through CDER or CBER and use it to apply for a Pre-Assign MF Number; or apply through the NextGen Portal.
ESG Account Application: Register through a WebTrader account; or apply through an AS2 account.
Organize filing materials according to eCTD requirements: Should include a cover letter and complete administrative and technical information in appropriate eCTD modules, mainly involving the following modules:
Module 1: Includes cover letter, administrative information (DMF holder, contact person/agent, manufacturer information, debarment certification, etc.), reference materials (Letter of Authorization (LOA), list of authorized persons, etc.), application status, meetings, information amendments, other correspondence, etc.
Module 2: Summarizes relevant parts of Module 3 and Modules 4 and 5 (if applicable).
Module 3: Content varies by DMF type.
Module 4: Required only if the DMF contains non-clinical evaluations, such as those supporting the safety of excipients or impurities.
Module 5: Submits only clinical information, such as that in Type V DMFs.
Upload through ESG and submit to the FDA.
IV. Subsequent Submissions
Amendments, additions, or deletions of information in the DMF (including LOAs) must be submitted to the DMF. These subsequent submissions should contain a cover letter and, if necessary, updated administrative and technical information. Notifications of changes to the DMF holder's name and acceptance notifications should also include a statement of commitment.
All amendments and LOAs should reference the updated DMF. A cumulative change history should be submitted with each subsequent submission.
DMF holders must notify affected authorized parties of any changes, additions, or deletions to the DMF and should provide sufficient information to enable authorized parties to determine the appropriate reporting procedure for their applications. This notification should be sent well in advance of any changes to allow authorized parties to report application changes within an appropriate timeframe.
V. FDA Processing and Review Policies
Administrative Review: If the administrative information in the original DMF is acceptable, the FDA will send an acknowledgment letter to the holder; if the information is incomplete, the holder will be contacted to request supplements; technical review can only proceed after all administrative issues are resolved and the DMF is referenced in an application or another DMF; the FDA will check whether subsequent submissions match and contact the holder to request corrections if administrative issues are found.
Technical Review: When an authorized party submits a copy of the DMF holder's LOA in its application or another DMF, the FDA will conduct a comprehensive review of the referenced technical information in the DMF. The review result depends on the specific use of the DMF described in the application or other DMF; reviewers may request additional information or determine that the DMF cannot support the relevant application and will contact the holder and agent.
Although DMF is crucial for drug registration, enterprises often face multiple challenges in practical operations, such as high regulatory complexity, high thresholds for technical documents, and significant pressure in process management... Beijing BrilliantMed Pharma Tech Co., Ltd., as a professional service institution deeply engaged in the field of pharmaceutical compliance, provides customized DMF submission solutions for enterprises with its full-chain capabilities of "regulatory interpretation + technical support + process management", making the path to compliance more efficient and worry-free:
In-depth compliance interpretation to accurately meet FDA requirements
Full-process document management to ensure zero errors in submission
Preparatory work: Assisting enterprises in obtaining pre-assigned DMF numbers, planning eCTD document structures, and ensuring the completeness and accuracy of administrative information (such as holder information, agent authorization).
Document preparation: Customizing technical content according to DMF types, including descriptions of production processes, quality standards, stability data, etc., and simultaneously completing English translation and format verification.
Follow-up management: Tracking FDA administrative and technical review feedback, efficiently handling supplementary requirements; assisting in submitting annual reports and managing LOA authorization lists to ensure the DMF remains valid.
Experience-driven to accelerate the review process: BrilliantMed, with rich experience, is familiar with FDA review logic and common problem points.
Choose BrilliantMed to make DMF an "accelerator" for drug listing.
In the highly competitive U.S. pharmaceutical market, efficient DMF submission is a key link for rapid drug approval. BrilliantMed, with professional, rigorous, and efficient services, helps enterprises overcome compliance barriers and focus more energy on core research and development and production. Whether you are an innovative pharmaceutical company submitting DMF for the first time or an established enterprise needing to optimize existing documents, BrilliantMed can provide tailored solutions, making every DMF a "passport" for drug listing.